Strategy

Jul 30, 2007
Pharmaceutical Executive
Avandia's market share erosion was magnified further by the almost complete absence of new prescriptions being switched to Avandia from its competitors. In the weeks before the event, Avandia accounted for more than 20 percent of all switches by primary care physicians
Jul 30, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Tibotec is set to launch a second revolution in HIV treatment—­and make a run at Glaxo, BMS, and Abbott, the longtime market kingpins
Jul 30, 2007
Pharmaceutical Executive
A new class of scales that can help capture drug effects—not necessarily disease impacts, as quality-of-life instruments currently do—will likely be needed to identify the meaning of the drug's benefits to patients
Jul 25, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Severin Schwan takes over at Roche
Jul 18, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In the wake of a high-profile death from counterfeit drugs, the industry reacts
Jul 03, 2007
Pharmaceutical Executive
What's old and established is in, what's new—and once interpreted as"better"—is out
Jul 03, 2007
Pharmaceutical Executive
It's bittersweet being one of the leaders of an industry that is not sustainable," a top pharma CEO recently told Carolyn Buck Luce, Ernst & Young's global pharmaceutical sector leader. Bittersweet is a poignant word for a hard-driving exec to issue.
Jun 27, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Global market will be twice as big by 2020, but industry needs new vision
Jun 01, 2007
Pharmaceutical Executive
It was like the end of the arms race last November when Pfizer announced it was slashing its national sales force by 20 percent. Coolly downplayed as cost-cutting by new CEO Jeffrey Kindler, the stunning move was met by industry insiders, Wall Street analysts, and the media with one humongous collective sigh of relief. Big Pharma was seen as having grown dangerously addicted to the detailing game over the past decade, with the top firms plowing more and more of their blockbuster profits into trying to keep up with Pfizer's "flood the zone" strategy and with less and less to show for it.
Jun 01, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches.
native1_300x100
lorem ipsum